What are the diagnostic tests available based on nccn
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Based on the patient's clinical summary, I'll outline the relevant diagnostic testing recommendations for Glioblastoma Multiforme (GBM) according to authoritative sources:
According to the NCCN Clinical Practice Guidelines for Central Nervous System Cancers, the standard diagnostic workup should include:
- Imaging Studies:
- MRI with and without contrast (which the patient has received, as evidenced by the documentation of enhancing lesions)
- Advanced imaging techniques such as: • MR Spectroscopy • Perfusion imaging • Diffusion imaging • PET imaging (the patient has already undergone C11-methionine PET imaging, as noted in the summary)
- Molecular Testing (NCCN Category 1 recommendation):
- IDH mutation status
- MGMT promoter methylation status
- 1p/19q codeletion testing
- ATRX mutation
- TERT promoter mutation
The National Cancer Institute (NCI) additionally recommends:
- Regular neurological examinations
- Cognitive function assessments
- Performance status evaluation (which is documented as 0 in this case)
Important note from the clinical summary:
- The document states "Molecular testing details not specified in available records" - this suggests a potential gap in documented testing that should be addressed according to current guidelines.
ASCO Guidelines also emphasize:
- The importance of regular surveillance imaging to monitor treatment response and disease progression
- The need for ongoing seizure assessment and management (particularly relevant given the patient's recent seizure history)
Recommendation based on guidelines: Since molecular testing details are not specified in the records, it would be important to verify whether comprehensive molecular testing has been performed according to current NCCN guidelines, as this could impact treatment decisions and clinical trial eligibility.
Always consult with healthcare providers for specific testing recommendations, as individual cases may require modified approaches based on clinical circumstances.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with diagnosis for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ